Life Sciences & Biotechnology
Title : | Biocomposites based on Liquid Exfoliated Transition Metal Dichalcogenides for Orthopaedic Applications: Osteogenic Differentiation of Mesenchymal stem Cells, and Bone Formation study in Rabbit Models |
Area of research : | Life Sciences & Biotechnology |
Principal Investigator : | Dr. Rohan shetty, Yenepoya (Deemed To Be University), Mangaluru, Karnataka |
Timeline Start Year : | 2023 |
Timeline End Year : | 2026 |
Contact info : | shettyrohan@rediffmail.com |
Details
Executive Summary : | The primary goal of this research is to develop highly bioactive and mechanically robust composites containing poly lactic-co-glycolic acid-mesoporous bioactive glass with molybdenum diselenide nanosheets-simvastatin (PLGA-MBG-Mose2-simvastatin) composites for bone regeneration. Over 2 million bone grafts are performed worldwide. Autograft and allograft are two commonly used methods to treat bone defects. Recently, synthetic graft-based biomaterials have received a lot of attention in the treatment of bone-related diseases. Transition metal dichalcogenides (TMDs-Mos2, Ws2, Mose2 and Wse2) draw much attention to bone tissue engineering due to their high surface area and bioactivity. TMDs can accelerate bone-forming ability once implanted into the human body. However, despite high bioactivity, TMDs alone cannot mimic the natural function of bone. Mose2 and mesoporous bioactive glass (MBG) has numerous potential uses in tissue engineering applications. In the proposed effort, we intend to synthesize the MBG using the structure-directing agent Pluronic F-127. In addition, a nano-structured Mose2, osteostimulant drug simvastatin, and PLGA polymer were utilized in the hybrid system to accelerate osteogenic differentiation for bone tissue repair and regeneration. The scaffolds will be fabricated using compressive molding technology with MBG, and Mose2 can retain the osteostimulant drug simvastatin, while the polymer PLGA was used to seal the mesostructured, which facilitates the sustainable release of a drug. The scaffolds can interact with animal-derived bone marrow mesenchymal stem cells (MsCs) for osteogenic differentiation. Furthermore, the biocompatibility of the scaffolds will be checked by using an adhesion test, alkaline phosphatase, live-dead staining assay, and WsT-1 assay. The A rabbit model will be carried out to investigate the potential of PLGA-MBG-Mose2-simvastatin to understand the bone-forming potential of the composites. We propose three objectives to complete the overall project. The first objective of the proposal is to prepare the poly lactic-co-glycolic acid-mesoporous bioactive glass with molybdenum diselenide nanosheets-simvastatin composites, and the second objective will be the interaction of stem cells. The final aim of the work will be to investigate the bone formation efficiency of the developed scaffold with rabbit femur mode. The developed materials will have multiple applications in terms of bone graft substitutes. The expanded bone graft will be utilized in long bone fractures, bone issues with congenital disabilities, bone tumor resection and bone graft in dental implantation. The developed PLGA-MBG-Mose2-simvastatin will be an excellent and unique biomaterial for treating bone disorders. |
Co-PI: | Dr. Jayachandran Venkatesan, Yenepoya (Deemed To Be University), Mangaluru, Karnataka-575018 |
Total Budget (INR): | 24,46,400 |
Organizations involved